Consideration of rheumatoid arthritis (RA) as an autoimmune disease includes initiating event(s), genetic predisposition, immune regulatory derangements, and effector cycles of articular damage. The initiating event is still unknown. Collagen type 2 has good claims as a rheumatogenic autoantigen which perpetuates disease. The association of HLA DR4 with rheumatoid arthritis is in part explainable by the affinity of binding of the rheumatogenic antigen to a hypervariable portion of MHC Class II molecules with selective presentation of this complex to T cell receptors. Immune regulatory derangements include lymphokine-induced aberrant expression of MHC Class II molecules on synovial tissues, the presence of a 'resistant' subset of B cells (CD5 + ve), failure of anti-idiotypic control of autoantibodies (not well established as yet in rheumatoid arthritis), and defective immune suppression, revealed by low counts in synovial fluids of a suppressor-inducer subset of CD4 +ve T cells. The many possibilities for therapeutic immune intervention would include polyclonal or monoclonal antibody to block (a) receptors for antigen on B or T lymphocytes (but this would require knowledge of the rheumatoid arthritis-inducing antigen), (b) the CD4 complex on helper T lymphocytes, (c) MHC Class II (la) molecules, for which there are excellent prototypes in experimental immunopathology, or (d) lymphokines or their receptors. Induction of suppresion by 'tolerogenic vaccines' is experimentally validated, but only for diseases for which an autoantigen can be identified.
Introduction
A recent paper on Type I diabetes mellitus (Type I DM) contained the comment 'Only when the innermost mechanisms of immune reactions are understood, specific immunotherapy will become a standard tool in the clinical management of diabetes'. Since an understanding of immunological dysfunction in the pathogenesis of Type I DM1 is probably closer than for many other autoimmune diseases, including rheumatoid arthritis,2 it could be premature even to consider immunotherapy for rheumatoid arthritis. Yet many current therapies of immune-mediated diseases are based on no more than a general principle of reduction of lymphocyte activity, the expectation being that the particular treatment will attenuate the activity of pathogenic autoreactive lymphocytes without being overly prejudicial to the function of normal lymphocyte populations.
The cause of rheumatoid arthritis and the 'innermost mechanisms of immune reactions' in this disease has been investigated from many directions, notably immunology, genetics, biochemistry, pharmacology, microbiology and epidemiology, with the following pathogenetic scenarios constructed: 1 . an initiating event presumed to be infectious, and which may contribute a residual intrasynovial antigen, although this has never been convincingly demonstrated; 2. a genetic predisposition contributing up to 30% of the risk for the disease; 3. an immune regulatory disorder in which suppressor systems fail to limit an unwanted immune response to the postulated intrasynovial antigen; 4 . immunopathogenetic events sequential to [1] [2] [3] which create secondary cycles ( 
